A thorough QT/QTc study of clinical and supra-therapeutic doses of preladenant in volunteers.

Trial Profile

A thorough QT/QTc study of clinical and supra-therapeutic doses of preladenant in volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2013

At a glance

  • Drugs Preladenant (Primary) ; Moxifloxacin
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Jul 2013 New trial record
    • 16 Jul 2013 Results published in the European Journal of Clinical Pharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top